Welcome to our dedicated page for Globus Med news (Ticker: GMED), a resource for investors and traders seeking the latest updates and insights on Globus Med stock.
Globus Medical Inc (NYSE: GMED) drives innovation in musculoskeletal solutions and surgical robotics, delivering cutting-edge technologies for spinal and orthopedic procedures. This dedicated news hub provides investors and medical professionals with essential updates on the company's advancements in medical device innovation.
Key Resources: Access official press releases, financial announcements, and strategic partnership updates in one centralized location. Track developments in robotic-assisted surgery platforms, regulatory milestones for spinal implants, and clinical trial progressions shaping modern surgical care.
Content Focus: Our curated collection includes earnings reports, product launch details, FDA clearance announcements, and technology partnership disclosures. Stay informed about GMED's expanding portfolio of enabling technologies designed to enhance surgical precision and patient outcomes.
Stay Updated: Bookmark this page for real-time access to verified information about Globus Medical's market-moving developments. Regularly refreshed content ensures you maintain awareness of critical innovations in the evolving medical devices sector.
Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, has scheduled its second quarter 2024 earnings release for Tuesday, August 6, 2024, after market close. The company will host a teleconference at 4:30 p.m. Eastern Time to discuss its financial performance with the investment community.
Interested parties can access the conference call via webcast on the Investors page of Globus Medical's website or by telephone after registering in advance. The audio archive will be available on the company's Investor page following the call.
Globus Medical, Inc. reported strong financial results for the first quarter of 2024 with worldwide net sales reaching $606.7 million, marking a significant increase of 119.3% over the previous year. The company's GAAP net loss was $7.1 million, with a GAAP diluted EPS of ($0.05) and non-GAAP diluted EPS of $0.72. The company's focus on integration following the NuVasive merger has led to positive outcomes, positioning them well for the future. The updated guidance for full year 2024 revenue and earnings also shows an increase over previous estimates.
FAQ
What is the current stock price of Globus Med (GMED)?
What is the market cap of Globus Med (GMED)?
